Warning: The NCBI web site requires JavaScript to function. more...
Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection.
Glazko GV, Babenko VN, Koonin EV, Rogozin IB.
Biol Direct. 2006 Jan 31;1:4.
Related citations
Mutation hotspots in the p53 gene in tumors of different origin: correlation with evolutionary conservation and signs of positive selection.
Glazko GV, Koonin EV, Rogozin IB.
Biochim Biophys Acta. 2004 Aug 12;1679(2):95-106.
Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.
Babenko VN, Basu MK, Kondrashov FA, Rogozin IB, Koonin EV.
BMC Cancer. 2006 Feb 9;6:36.
Theoretical analysis of mutation hotspots and their DNA sequence context specificity.
Rogozin IB, Pavlov YI.
Mutat Res. 2003 Sep;544(1):65-85. Review.
p53 gain-of-function: tumor biology and bioinformatics come together.
Koonin EV, Rogozin IB, Glazko GV.
Cell Cycle. 2005 May;4(5):686-8. Epub 2005 May 28.
Oncogenic pathways in hereditary and sporadic breast cancer.
Kenemans P, Verstraeten RA, Verheijen RH.
Maturitas. 2008 Sep-Oct;61(1-2):141-50.
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.
Cancer Res. 2009 Apr 15;69(8):3625-33. Epub 2009 Mar 31.
Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors.
Zientek-Targosz H, Kunnev D, Hawthorn L, Venkov M, Matsui S, Cheney RT, Ionov Y.
Mol Cancer. 2008 Jun 5;7:51.
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, Guinebretière JM, Marian C, Barrois M, Boitier F, Lenoir GM, Bressac-de Paillerets B.
Fam Cancer. 2007;6(4):453-61. Epub 2007 Jul 12.
BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R, Hussain I, Afroze D, Aejazaziz S, Jan M, Shah ZA, Das BC, Siddiqi MA.
Cancer Lett. 2007 Apr 18;248(2):308-20. Epub 2006 Sep 22.
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M.
Hum Mutat. 2007 Jun;28(6):622-9.
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN.
Breast Cancer Res Treat. 2008 Apr;108(3):399-408. Epub 2007 May 31.
G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
Kouidou S, Malousi A, Kyventidis A, Fragou A, Maglaveras N.
Breast Cancer Res Treat. 2007 Dec;106(3):351-60. Epub 2007 May 16.
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L, Wang F, Qian C, Neumann RM, Cheville JC, Tindall DJ, Liu W.
Hum Mutat. 2006 Oct;27(10):1062-3.
iMARS--mutation analysis reporting software: an analysis of spontaneous cII mutation spectra.
Morgan C, Lewis PD.
Mutat Res. 2006 Jan 31;603(1):15-26. Epub 2005 Dec 15.
Hypermutable non-synonymous sites are under stronger negative selection.
Schmidt S, Gerasimova A, Kondrashov FA, Adzhubei IA, Kondrashov AS, Sunyaev S.
PLoS Genet. 2008 Nov;4(11):e1000281. Epub 2008 Nov 28. Erratum in: PLoS Genet. 2008 Nov;4(11).doi.org/10.1371/annotation/a81b1fab-890c-447b-a308-5bc8ca3eb21d.. Adzuhbei, Ivan A [corrected to Adzhubei, Ivan A].
Human germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies.
Cole DN, Carlson JA, Wilson VL.
Environ Mol Mutagen. 2008 Jul;49(6):417-25.
TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K, Rannala B, Traisathit P, Srikummool M, Wongchai Y, Kangwanpong D.
Cancer Genet Cytogenet. 2008 Aug;185(1):20-7.
Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Abdelmohsen K, Gorospe M, Kern SE.
Cell Cycle. 2006 May;5(10):1090-3. Epub 2006 May 15.
Significance of CpG methylation for solar UV-induced mutagenesis and carcinogenesis in skin.
Ikehata H, Ono T.
Photochem Photobiol. 2007 Jan-Feb;83(1):196-204. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on